Antiestrogens upregulate estrogen receptor β expression and inhibit adrenocortical H295R cell proliferation

Journal of Molecular Endocrinology

Volumn 35, Issue 2, 2005, Pages 245-256

  Montanaro, D ^b   Maggiolini, M ^b   Recchia, A G ^b   Sirianni, R ^b   Aquila, S ^b   Barzon, L ^a   Fallo, F ^a   Ando S ^b   Pezzi, V ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF CALABRIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; ANDROGEN; ANTIESTROGEN; AROMATASE; CASPASE 3; CASPASE 8; CYTOCHROME P450; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FAS LIGAND; FULVESTRANT; THYMIDINE;

ADRENAL CORTEX TUMOR; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; CELL FUNCTION; CELL GROWTH; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG MECHANISM; ENZYME DEGRADATION; GENE EXPRESSION REGULATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MORPHOLOGY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; RECEPTOR UPREGULATION; TUMOR CELL LINE; TUMOR GROWTH;

ADRENAL CORTEX; ADRENAL CORTEX NEOPLASMS; ANDROGENS; ANTIGENS, CD95; APOPTOSIS; AROMATASE; AROMATASE INHIBITORS; AUTOCRINE COMMUNICATION; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGEN RECEPTOR MODULATORS; FAS LIGAND PROTEIN; FORSKOLIN; HUMANS; MEMBRANE GLYCOPROTEINS; NITRILES; PROMOTER REGIONS (GENETICS); RNA, MESSENGER; TRIAZOLES; TUMOR NECROSIS FACTORS;

EID: 27644504201     PISSN: 09525041     EISSN: None     Source Type: Journal    
DOI: 10.1677/jme.1.01806     Document Type: Article

References (49)

1. Albrecht ED, Babischkin JS, Davies WA, Leavitt MG & Pepe GJ 1999 Identification and developmental expression of the estrogen receptor alpha and beta in the baboon fetal adrenal gland. Endocrinology 140 5953-5961.
2. Andrews NC & Faller DV 1991 A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Research 19 2499.
3. Bardon S, Vignon F, Montcourrier P & Rochefort H 1987 Steroid receptor-mediated cytotoxicity of an antiestrogen and an antiprogestin in breast cancer cells. Cancer Research 47 1441-1448.
4. Barzon L, Chilosi M, Fallo F, Martignoni G, Montagna L, Palu G & Boscaro M 2001 Molecular analysis of CDKN1C and TP53 in sporadic adrenal tumors. European Journal of Endocrinology 145 207-212.
5. Barzon L, Sonino N, Fallo F, Palu G & Boscaro M 2003 Prevalence and natural history of adrenal incidentalomas. European Journal of Endocrinology 149 273-285.
6. KIP2 are involved in proliferation of malignant sporadic adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism 85 322-330.
7. Bradford MM 1976 A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry 72 248-254.
8. Chan TW, Pollak M & Huyunh H 2001 Inhibition of insulin-like growth factor signaling pathways in mammary gland by pure antiestrogen ICI 182,780. Clinical Cancer Research 7 2545-2554.
9. Dupont J, Karas M & LeRoith D 2000 The potentiation of estrogen on insulin-like growth factor I action in MCF-7 human breast cancer cells includes cell cycle components. Journal of Biological Chemistry 275 35893-35901.
10. Ellis PA, Saccani-Jotti G, Clarke R, Johnston SRD, Anderson E, Howell A, A'Hern R, Salter J, Detre S, Nicholson R et al. 1997 Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer. International Journal of Cancer 72 608-613.
11. Gao X, Loggie BW & Nawaz Z 2002 The roles of sex steroid receptor coregulators in cancer. Molecular Cancer 1 7.
12. Gazdar AF, Cie HK, Shackleton CH, Chen TR, Triche TJ, Myers CE, Chrousos GP, Brennan MF, Stein CA & La Rocca RV 1990 Establishment and characterization of a human adrenocortical carcinoma cell line that expresses multiple pathways of steroid biosynthesis. Cancer Research 50 5488-5496.
13. Gicquel C, Raffin-Sanson M, Gaston V, Bertagna X, Plouin P, Schlumberger M, Louvel A, Luton J & Le Bouc Y 1997 Structural and functional abnormalities at 11p15 are associated with the malignant phenotype in sporadic adrenocortical tumors. Study on a series of 82 tumors. Journal of Clinical Endocrinology and Metabolism 87 2559-2565.
14. Hamelers IHL & Steenbergh PH 2003 Interactions between estrogen and insulin-like growth factor signaling pathways in human breast tumor cells. Endocrine-related Cancer 10 331-345.
15. Hirst JJ, West NB, Brenner RM & Novy MJ 1992 Steroid hormone receptors in the adrenal glands of fetal and adult rhesus monkeys. Journal of Clinical Endocrinology and Metabolism 75 308-314.
16. Hsing AW, Nam JM, Co Chien HT, McLaughlin JK & Fraumeni Jr JF 1996 Risk factors for adrenal cancer: an exploratory study. International Journal of Cancer 65 432-436.
17. Huynh H, Yang X & Pollak M 1996 Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells. Journal of Biological Chemistry 271 1016-1021.
18. Jones PS, Parrott E & White IN 1999 Activation of trascription by estrogen receptor alpha and beta is cell type- and promoter-dependent. Journal of Biological Chemistry 274 32008-32014.
19. Kirschner LS 2002 Signaling pathways in adrenocortical cancer. Annals of the New York Academy of Sciences 968 222-239.
20. Koshida S, Narita Tsutomu, Kato H, Yoshida S, Taga T, Ohta S & Takeuchi Y 2002 Estrogen receptor expression and estrogen receptor-independent cytotoxic effects of tamoxifen on malignant rhabdoid tumor cells in vitro. Japanese Journal of Cancer Research 93 1351-1357.
21. Lee AV, Jackson JG, Gooch JL, Hilsenbeck SG, Coronado-Heinsohn E, Osborne CK & Yee D 1999 Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Molecular Endocrinology 13 787-796.
22. Lephart ED & Simpson ER 1991 Assay of aromatase activity. Methods in Enzymology 206 477-483.
23. Li LC, Yeh CC, Nojima D & Dahiya R 2000 Cloning and caracterization of human estrogen receptor β promoter. Biochemistry and Biophysics Research Communications 275 682-689.
24. Logié A, Boulle N, Gaston V, Perin L, Boudou P, Le Bouc Y & Gicquel C 1999 Autocrine role of IGF-II in proliferation of human adrenocortical carcinoma NCI H295R cell line. Journal of Molecular Endocrinology 23 23-32.
25. Maggiolini M, Donzè O & Picard D 1999 A non-radioactive method for inexpensive quantitative RT-PCR. Biological Chemistry 380 695-697.
26. Mandlekar S & Kong AN 2001 Mechanisms of tamoxifen-induced apoptosis. Apoptosis 6 469-477.
27. Mor G, Kohen F, Garcia-Velasco J, Nilsen J, Brown W, Song J & Naftolin F 2000 Regulation of Fas ligand expression in breast cancer cells by estrogen: functional differences between estradiol and tamoxifen. Journal of Steroid Biochemistry and Molecular Biology 73 185-194.
28. Nagarkatti N 2000 Tumor-derived FasL induces toxicity in lymphoid organs and plays an important role in successful chemotherapy. Cancer Immunology and Immunotherapy 49 46-55.
29. Nagarkatti N & Davis BA 2003 Tamoxifen induces apoptosis in Fas+ tumor cells by upregulating the expression of Fas ligand. Cancer Chemotherapy and Pharmacology 51 284-290.
30. Nilsen J, Mor G & Naftolin F 2000 Estrogen-regulated developmental neuronal apoptosis is determined by estrogen receptor subtype and the Fas/Fas ligand system. Journal of Neurobiology 43 64-78.
31. Nilsson S, Makela S, Treuter E, Tujague M, Thomsen J, Andersson G, Enmark E, Pettersson K, Warner M & Gustafsson JA 2001 Mechanisms of estrogen action. Physiology Reviews 81 1535-1565.
32. Paech K, Webb P, Kuiper GGJM, Nilsson S, Gustafsson JÅ, Kushner PJ & Scanlan TS 1997 Differential ligand activation of estrogen receptor ERα and ERβ at AP1 sites. Science 277 1508-1510.
33. Paige LA, Christensen DJ, Gron H, Norris JD, Gottlin EB, Padilla KM, Chang CY, Ballas LM, Hamilton PT, McDonnell DP & Fowlkes DM 1999 Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta. PNAS 96 3999-4004.
34. Rainey WE, Bird IM & Mason JI 1994 The NCI-H295 cell line: a pluripotent model for human adrenocortical studies. Molecular and Cellular Endocrinology 100 45-50.
35. Rossi R, Zatelli MC, Valentini A, Cavazzini P, Fallo F, del Senno L & degli Uberti EC 1998 Evidence for androgen receptor gene expression and growth inhibitory effect of dihydrotestosterone on human adrenocortical cells. Journal of Endocrinology 159 373-380.
36. Somjen D, Stern N, Knoll E, Sharon O, Gayer B, Kulik T & Kohen F 2003 Carboxy derivatives of isoflavones as affinity carriers for cytotoxic drug targeting in adrenocortical H295R carcinoma cells. Journal of Endocrinology 179 395-403.
37. Stewart AJ, Johnson MD, May FE & Westley BR 1990 Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. Journal of Biological Chemistry 265 21172-21178.
38. Suda T, Takahashi T, Golstein P & Nagata S 1993 Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75 1169-1178.
39. Takahashi T, Tanaka M, Brannan CI, Jenkins NA, Copeland NG, Suda T & Nagata S 1994 Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 76 969-976.
40. Takeyama J, Suzuki T, Inoue S, Kaneko C, Nagura H, Harada N & Sasano H 2001 Expression and cellular localization of estrogen receptors alpha and beta in the human fetus. Journal of Clinical Endocrinology and Metabolism 86 2258-2262.
41. Uht RM, Webb P, Nguyen P, Price Jr RH, Valentine C, Favre H & Kushner PJ 2004 A conserved lysine in the estrogen receptor DNA binding domain regulates ligand activation profiles at AP-1 sites, possibly by controlling interactions with a modulating repressor. Nuclear Receptor 2 2.
42. Van Den Bemd JG, Kuiper GG, Pols HA & Van Leeuwen JP 1999 Distinct effects on the conformation of estrogen receptor alpha and beta by both the antiestrogens ICI 164,384 and ICI 182,780 leading to opposite effects on receptor stability. Biochemistry and Biophysics Research Communications 261 1-5.
43. Walker PR, Saas P & Dietrich PY 1997 Role of Fas ligand (CD95 L) in immune escape: the tumor cell strikes back. Journal of Immunology 158 4521-4524.
44. Warri AM, Huovinen RL, Laine AM, Martikainen PM & Harkonen K 1993 Apoptosis in toremifene-induced growth inhibition of human breast cancer cells in vivo and in vitro. Journal of the National Cancer Institute 85 1412-1418.
45. Watanabe M & Nakaijn S 2004 Forskolin up-regulates aromatase (CYP19) activity and gene transcripts in the human adrenocortical carcinoma cell line H295R. Journal of Endocrinology 180 125-133.
46. Weatherman RV & Scanlan TS 2001 Unique protein determinants of the subtype-selective ligand responses of the estrogen receptors (ERalpha and ERbeta) at AP-1 sites. Journal of Biological Chemistry 276 3827-3832.
47. Webb P, Valentine C, Nguyen P, Price Jr RH, Marimuthu A, West BL, Baxter JD & Kushner PJ 2003 ERbeta binds N-CoR in the presence of estrogens via an LXXLL-like motif in the N-CoR C-terminus. Nuclear Receptor 1 4.
48. Weber MM, Fottner C & Wolf E 2000 The role of the insulin-like growth factor system in adrenocortical tumourigenesis. European Journal of Clinical Investigation 30 69-75.
49. Wilson JW, Wakeling AE, Morris ID, Hickman JA & Dive C 1995 MCF-7 human mammary adenocarcinoma cell death in vitro in response to hormone-withdrawal and DNA damage. International Journal of Cancer 61 502-508.